HASBROUCK HEIGHTS, N.J., June 7, 2010 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today that Paul Averback, MD, DABP, President and Chief Executive Officer of Nymox, will be providing a corporate summary and a presentation regarding the Company's ongoing clinical program for NX-1207 at the Jefferies 2010 Global Life Sciences Conference in New York on June 9, 2010 at 4:30 p.m. Eastern Time. NX-1207 is a novel patented drug developed by Nymox which is currently in Phase 3 trials in the United States for the treatment of benign prostatic hyperplasia (BPH), a common affliction of older men. It is estimated that more than 100 million men worldwide suffer from the symptoms of BPH. Nymox is a biotechnology company engaged in the research and development of therapeutics and diagnostics, with a particular emphasis on products targeted for the unmet needs of the aging population. More information about Nymox is available at www.nymox.com, email: firstname.lastname@example.org, or 800-936-9669. This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.
CONTACT: Nymox Pharmaceutical Corporation Roy Wolvin 1-800-93NYMOX www.nymox.com